Genomic Health, Inc.

07.09.2018 – 11:17
German Health Technology Assessment Body (IQWiG) Concludes Only Oncotype DX® Has Sufficient Evidence to Guide Breast Cancer Adjuvant Chemotherapy Decisions Based on Landmark TAILORx Study Results
Geneva (ots/PRNewswire) - Updated Assessment of Breast Cancer Gene Expression Profiling Tests for Clinical Use in Germany Final German Federal Joint Committee (G-BA) Reimbursement Decision Expected by End of 2018 Genomic Health today announced the publication of an updated assessment ...
mehr
21.03.2012 – 08:03
Genomic Health Announces Presentation of Three Oncotype DX® Studies at the 8th European Breast Cancer Conference
Geneva (ots/PRNewswire) - Results Reconfirm Test's Cost-Effectiveness, Emphasise Important Role in Guiding Treatment Decisions Genomic Health, Inc. today announced results of three new Oncotype DX(R) studies including data demonstrating the test's cost-effectiveness within the German and Hungarian healthcare ...
mehr
26.06.2009 – 09:11
Genomic Health Reports Favorable Commentary on Value of Multigene Assays From the St. Gallen Expert Consensus Meeting on the Primary Treatment of Early Breast Cancer
Geneva, and Redwood City, California (ots/PRNewswire) - - Guidelines Specify that Validated Molecular Assays Should be Considered as an Adjunct to Standard Measures in Helping Determine Chemotherapy Benefit - Genomic Health, Inc. (Nasdaq: GHDX) today reported that the St. Gallen International Consensus ...
mehr